Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/2003
08/26/2003US6610287 Methods of gene delivery to cells in the nervous system by introducing and expressing gene sequences mediated by herpes simplex virus 1 (HSV-1) vectors with a mutation in a gene for viral replication. Methods for modulating neuronal physiology
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/21/2003WO2003069347A2 Diagnostic and therapeutic use of caps
08/21/2003WO2003069311A2 Methods and compositions for use in spliceosome mediated rna trans-splicing
08/21/2003WO2003068959A1 Novel screening method
08/21/2003WO2003068954A2 Microorganism for genetic therapeutic treatment of proliferative diseases
08/21/2003WO2003068952A1 Stat3 activated stem cell
08/21/2003WO2003068944A2 METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
08/21/2003WO2003068939A2 Cks1 INHIBITORS
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068930A2 Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof
08/21/2003WO2003068925A2 Production of a protein delivery system for in vivo therapeutic treatment
08/21/2003WO2003068912A2 PSEUDOMONAS SYRINGAE HARPINS, HopPtoP AND HopPmaHPTO, AND THEIR USES
08/21/2003WO2003068819A1 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068809A2 An herpes simplex virus complex
08/21/2003WO2003068797A1 Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
08/21/2003WO2003068794A1 Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof
08/21/2003WO2003068270A1 Method of radio-labelling biomolecules
08/21/2003WO2003068257A1 Cancer therapy
08/21/2003WO2003068190A1 Intracellular delivery of therapeutic agents
08/21/2003WO2003068169A2 Stabilized synthetic immunogen delivery system
08/21/2003WO2003068165A2 Angiopoietin-1 in the treatment of disease
08/21/2003WO2003068155A2 Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003048352A3 Histone h3 methyltransferase polypeptide
08/21/2003WO2003046138A3 Genetically stable expression vector
08/21/2003WO2003042245A3 Growth hormone variations in humans and their uses
08/21/2003WO2003037254A3 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
08/21/2003WO2003025139A3 Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
08/21/2003WO2003015708A8 Composition and method for treating hiv infection
08/21/2003WO2002097127A3 Genes and proteins for prevention, prediction, diagnosis, prognosis and treatment of chronic lung disease
08/21/2003WO2002095030A3 Modulation of cd200 receptors
08/21/2003WO2002095027A3 Immunostimulatory oligodeoxynucleic molecules
08/21/2003WO2002083182A3 The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
08/21/2003WO2002082075A3 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
08/21/2003WO2002077236A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002072140A3 Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
08/21/2003WO2002068650A3 Modified and stabilized gdf propeptides and uses thereof
08/21/2003WO2002067861A3 Oncolytic adenoviral vectors
08/21/2003WO2002064776A3 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002062999A3 Proteins and nucleic acids encoding same
08/21/2003WO2002060467A3 Compositions and methods for improving kidney function
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002048405A3 Non-invasive method for detecting target rna
08/21/2003WO2002046224A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002044418A3 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
08/21/2003WO2002035240A3 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002020047A9 Chlamydial peptides and their mimics in demyelinating disease
08/21/2003WO2002010392A9 Mammalian dna binding membrane-associated protein-encoding gene and uses
08/21/2003WO2001090342A3 Genetic engineering of vascular grafts to resist disease
08/21/2003US20030159158 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
08/21/2003US20030158602 Contacting a cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of Nell-1 gene as compared to the expression of the NELL-1 gene in a cell that is not contacted with test agent
08/21/2003US20030158399 Compositions and methods for the treatment and diagnosis of immune disorders
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158149 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold
08/21/2003US20030158143 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers
08/21/2003US20030158141 Comprising virus, non-coding regulatory region of which is replaced by heterologous encoding sequence, wherein function of replaced regulatory region is dependent upon secondary structure and wherein encoding sequence has said function
08/21/2003US20030158137 Gene directed enzyme prodrug theraphy (gdept) for cell ablation
08/21/2003US20030158136 Materials and methods relating to immune responses to fusion proteins
08/21/2003US20030158134 Use of HIV Tat protein or polynucleotide, HIV Nef protein or polynucleotide, HIV Tat protein or polynucleotide linked to HIV Nef protein or polynucleotide and HIV gpl20 protein or polynucleotide in manufacture of vaccine against hiv
08/21/2003US20030158133 Use of such inhibitors or activators in treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments
08/21/2003US20030158132 Method for enhancing bone density or formation
08/21/2003US20030158130 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
08/21/2003US20030158112 Selective induction of apoptosis to treat ocular disease
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158092 For therapy of glycoprotein aberration disorders (e.g., cystic fibrosis), including gene therapy
08/21/2003US20030158085 For diagnosis and therapy of pancreatic disorders, particularly type I diabetes
08/21/2003US20030157718 Expression of heterologous genes from an IRES translational cassette in retroviral vectors
08/21/2003US20030157717 Linear DNA fragments for gene expression
08/21/2003US20030157711 STAT3 activated stem cell
08/21/2003US20030157691 Producing genetically engineered retrovirus comprising small interfering RNA (SiRNA) for prevention and treatment of human lymphadenopathy associated viral diseases
08/21/2003US20030157688 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
08/21/2003US20030157687 Comprises nucleotide sequences coding enzyme inhibitor (TIMP-4) for treatment of arthritis, cancer and scarring
08/21/2003US20030157678 Mitogenic oxygenases
08/21/2003US20030157599 Comprises nucleotide sequence coding prostaglandin E receptor (EP3) for diagnosis and treatment of atherosclerotic diseases; restriction fragment length polymorphisms
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
08/21/2003US20030157541 Central nervous system disorders; cardiovascular disorders;antiasthma agents
08/21/2003US20030157530 cDNA for human methylenetetrahydrofolate reductase
08/21/2003US20030157516 Medical diagnosis; binding with adenine
08/21/2003US20030157494 Smooth muscle cell promoter and uses thereof
08/21/2003US20030157485 Forensic analysis; chromosome marking
08/21/2003US20030157482 Binding labeled antibody to protein; measurement; calibration
08/21/2003US20030157142 Implants with a phosphazene-containing coating
08/21/2003US20030157130 Modified to include heterologous insertion downstream of its replicase open reading frames; insertion preferably comprises one or more protein-coding regions ideal for virus-like particles packaging
08/21/2003US20030157128 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen
08/21/2003US20030157124 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157123 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157121 Virulence genes, proteins, and their use
08/21/2003US20030157118 Tumour-specific animal proteins
08/21/2003US20030157116 Tlp peptides and dna sequences coding the same
08/21/2003US20030157110 Methods for the treatment of metabolic disorders, including obesity and diabetes
08/21/2003US20030157095 Invasive and metastic ability of breast cancer cells is proportional to level of peripheral type benzodiazepine receptor expressed, correlates with subcellular localization in that it is found in the nucleus of aggressive tumor cells
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157089 Polypeptides; inducting immunology response
08/21/2003US20030157082 Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
08/21/2003US20030157072 Gene expression; cell differentiation; anticancer agents
1 ... 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 ... 870